Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2009
12/17/2009US20090312305 Bicyclic compounds having activity at the cxcr4 receptor
12/17/2009US20090312301 Transition Metal Complexes for Inhibiting Resistance in the Treatment of Cancer and Metastasis
12/17/2009US20090312295 Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
12/17/2009US20090312290 Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
12/17/2009US20090312288 Kinase inhibitors
12/17/2009US20090312284 Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
12/17/2009US20090312280 Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
12/17/2009US20090312278 Treatment of cancers of the blood using selected glycomimetic compounds
12/17/2009US20090312277 Compositions And Methods For Reversing Or Preventing Resistance Of A Cancer Cell To A Cytotoxic Agent
12/17/2009US20090312276 Compositions and Methods for Treating Cancer
12/17/2009US20090312274 Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases
12/17/2009US20090312263 Gene Differentially Expressed in Breast and Bladder Cancer and Encoded Polypeptides
12/17/2009US20090312253 Methods of effecting Wnt signaling through Dkk structural analysis
12/17/2009US20090312251 Methods of regulating differentiation in mammals
12/17/2009US20090312245 SRA binding protein
12/17/2009US20090311780 Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
12/17/2009US20090311746 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
12/17/2009US20090311708 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression
12/17/2009US20090311413 Method and device for radiotherapy
12/17/2009US20090311351 Composition containing a cereal milling product
12/17/2009US20090311349 Method of quantification of multiple bioactives from botanical compositions
12/17/2009US20090311344 Dosing Regimen
12/17/2009US20090311343 Thiazole Compounds, and Compositions and Methods Using Same
12/17/2009US20090311332 Method for forming mesoporous silica nanoparticles, mesoporous silica nanopartices, and applications thereof
12/17/2009US20090311279 Colorectal Cancer Antigen
12/17/2009US20090311272 Methods and compositions for modulating angiogenesis and pericyte composition
12/17/2009US20090311268 Cd40-binding activating antibodies
12/17/2009US20090311264 Use of Disorazoles and Their Derivatives for the Treatment of Benign and Malignant Oncoses
12/17/2009US20090311262 Method for Diagnosing Cancers Expressing the HER2 Receptor or its Truncated Variants
12/17/2009US20090311259 maytansinoid drug moieties covalently linked by a linker to an antibody which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors; cancer
12/17/2009US20090311254 Cd40 antibody formulation and methods
12/17/2009US20090311249 Capecitabine Combination Therapy
12/17/2009US20090311245 Metalloproteinase 9 binding proteins
12/17/2009US20090311244 Screening Method
12/17/2009US20090311226 Composition and method for treating esophageal dysplasia
12/17/2009US20090311225 Compositions of and Methods of Using Stabilized PSMA Dimers
12/17/2009US20090311224 Therapeutic agent comprising lipocalin 2 against cancer metastasis, and methods of early diagnosis and inhibition of cancer metastasis using lipocalin 2
12/17/2009US20090311219 Oncolytic Adenoviruses for Cancer Treatment
12/17/2009US20090311218 Novel mutant interferon-alpha protein, particularly interferon-alpha subtype alpha 8; provides agents for susceptive diseases superior in anti-viral and anti-tumor actions compared with conventional agents for susceptive diseases; agents against tumors, viral diseases, and infection diseases
12/17/2009US20090311217 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
12/17/2009US20090311215 Method for treating cervical cancer
12/17/2009US20090311188 In vivo methods of identifying compounds which target suppressed cancer cells
12/17/2009US20090311183 Metalloproteinase 12 binding proteins
12/17/2009US20090311179 Selective Targeting of Apoptotic Cells
12/17/2009US20090311174 Method For Treating Cancer
12/17/2009US20090311173 Method and device for radiotherapy
12/17/2009DE102008015432A1 Verwendung von Pirinixinsäure-Derivaten zur Hemmung der Prostaglandin E2 Synthese Use of Pirinixinsäure derivatives for the inhibition of prostaglandin E2 synthesis
12/17/2009CA2727788A1 Treatment of cancers of the blood using selected glycomimetic compounds
12/17/2009CA2727680A1 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer
12/17/2009CA2727669A1 Novel derivatives of (bridged piperazinyl)-1-alcanone and use thereof as p75 inhibitors
12/17/2009CA2727595A1 Thiazole compounds, and compositions and methods using same
12/17/2009CA2727485A1 Iqgap3 epitope peptides and vaccines containing the same
12/17/2009CA2727389A1 5h-pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
12/17/2009CA2727082A1 Suppression of neuroendocrine diseases
12/17/2009CA2727073A1 Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
12/17/2009CA2727062A1 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
12/17/2009CA2726666A1 Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
12/17/2009CA2726114A1 Diazacarbazoles and methods of use
12/17/2009CA2726092A1 Suppression of cancers
12/17/2009CA2725755A1 Substituted pyrroles and methods of use
12/17/2009CA2725754A1 Diazacarbazoles and methods of use
12/17/2009CA2725295A1 Combination of spacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine
12/17/2009CA2725093A1 Azacarboline derivatives, preparation method thereof and therapeutic us of same
12/17/2009CA2721087A1 Anticancer methods using extracts of anemarrhena asphodeloides bunge
12/17/2009CA2720365A1 Bcr-complex-specific antibodies and methods of using same
12/16/2009WO2009154651A1 Treatment of metastic breast cancer by a combination of two anti-her2 antibodies and a taxene
12/16/2009EP2133365A2 Compositions and methods for the treatment of infections and tumors
12/16/2009EP2133349A1 Kinase inhibitors
12/16/2009EP2133335A1 Sphingosine compound, method for producing the same, and sphingomyelinase inhibitor
12/16/2009EP2133334A1 Heterocyclic derivatives as HDAC inhibitors
12/16/2009EP2133326A1 Novel pseudoglycolipid and use thereof
12/16/2009EP2133095A1 Pharmaceutical composition
12/16/2009EP2133094A1 Pharmaceutical composition
12/16/2009EP2133093A1 Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same
12/16/2009EP2132315A1 Reoviruses having modified sequences
12/16/2009EP2132228A1 Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
12/16/2009EP2132227A1 Composition of labeled and non-labeled monoclonal antibodies
12/16/2009EP2132220A1 Integrin targeted cyclopeptide ligands, their preparation and use
12/16/2009EP2132198A1 Solid forms of a raf kinase inhibitor
12/16/2009EP2132177A1 Pim kinase inhibitors and methods of their use
12/16/2009EP2132174A1 Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors
12/16/2009EP2131867A2 Modified hydroxypolymer conjugates with killing effect on tumor cells
12/16/2009EP2131866A2 Dual acting prodrugs
12/16/2009EP2131863A1 A method of treating malignant mesothelioma
12/16/2009EP2131849A1 Compositions and methods for delivery of anti-cancer agents
12/16/2009EP2131845A1 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
12/16/2009EP2131844A1 PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
12/16/2009EP2131836A1 Combination of imidazo ý1,5-a¨pyrazinyl derivatives with an agent that inhibits serine phosphorylation of irs1 for use in the treatment of cancer
12/16/2009EP2131821A1 Nanoparticle comprising rapamycin and albumin as anticancer agent
12/16/2009EP2131656A2 Phthalazine derivatives
12/16/2009EP2131655A2 Tri-aryl/heteroaromatic cannabinoids and use thereof
12/16/2009EP1904057B1 Hydroquinone ansamycins in the treatment of gastrointestinal stromal tumors
12/16/2009EP1830848B1 Use of thiazolidinone derivatives for the treatment of solid tumors
12/16/2009EP1576159B9 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
12/16/2009EP1521832B1 Anti-fragilis antibody and uses thereof
12/16/2009EP1434603B1 Method of treatment using ligand-immunogen conjugates
12/16/2009EP1322634B1 N-phenyl-2-pyrimidine-amine derivatives
12/16/2009EP1287147B1 Immunotoxin fusion proteins and means for expression thereof
12/16/2009EP0996455B1 Alpha-o-linked glycoconjugates with clustered (2,6)-st epitopes, methods of preparation and uses thereof
12/16/2009CN101605815A Method and arrangement for allowing enterprise and personal domains in the ims
1 ... 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 ... 2211